UPSTREAM BIO INC (UPB) Stock Overview
NASDAQ:UPB - US91678A1079 - Common Stock
UPB Key Statistics, Chart & Performance
The current stock price of UPB is 19.97 USD. In the past month the price increased by 26.07%.
UPB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.07 | 375.50B | ||
| AMGN | AMGEN INC | 13.01 | 152.70B | ||
| GILD | GILEAD SCIENCES INC | 14.86 | 142.76B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.38 | 101.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.56 | 60.77B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.25B | ||
| ARGX | ARGENX SE - ADR | 80.99 | 45.95B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.99 | 40.63B | ||
| INSM | INSMED INC | N/A | 30.67B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.03B | ||
| NTRA | NATERA INC | N/A | 23.06B | ||
| BIIB | BIOGEN INC | 8.79 | 20.62B |
Related stock screener links
About UPB
Company Profile
Upstream Bio, Inc. is a clinical-stage biotechnology company, which engages in the development of treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts and currently employs 52 full-time employees. The company went IPO on 2024-10-11. The firm is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. The company has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.
Company Info
UPSTREAM BIO INC
890 Winter Street, Suite 200
Waltham MASSACHUSETTS US
Employees: 52
Phone: 17812082466
UPSTREAM BIO INC / UPB FAQ
What is the stock price of UPSTREAM BIO INC today?
The current stock price of UPB is 19.97 USD. The price increased by 1.47% in the last trading session.
What is the ticker symbol for UPSTREAM BIO INC stock?
The exchange symbol of UPSTREAM BIO INC is UPB and it is listed on the Nasdaq exchange.
On which exchange is UPB stock listed?
UPB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for UPSTREAM BIO INC stock?
8 analysts have analysed UPB and the average price target is 76.5 USD. This implies a price increase of 283.07% is expected in the next year compared to the current price of 19.97. Check the UPSTREAM BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is UPSTREAM BIO INC worth?
UPSTREAM BIO INC (UPB) has a market capitalization of 1.08B USD. This makes UPB a Small Cap stock.
How many employees does UPSTREAM BIO INC have?
UPSTREAM BIO INC (UPB) currently has 52 employees.
What are the support and resistance levels for UPSTREAM BIO INC (UPB) stock?
UPSTREAM BIO INC (UPB) has a support level at 12.88 and a resistance level at 19.98. Check the full technical report for a detailed analysis of UPB support and resistance levels.
Is UPSTREAM BIO INC (UPB) expected to grow?
The Revenue of UPSTREAM BIO INC (UPB) is expected to grow by 21.55% in the next year. Check the estimates tab for more information on the UPB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy UPSTREAM BIO INC (UPB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of UPB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of UPB, evaluating the profitability, health, valuation and growth aspects
- UPSTREAM BIO INC (UPB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- UPSTREAM BIO INC (UPB) Sales and EPS estimates to see what analysts future expectations are.
- UPSTREAM BIO INC (UPB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- UPSTREAM BIO INC (UPB) Insider and Institutional Ownership to learn about the owners and their transactions.
- UPSTREAM BIO INC (UPB) Stock Chart to make your own analysis
- UPSTREAM BIO INC (UPB) Latest news and press-releases to stay up to date.
Does UPSTREAM BIO INC (UPB) stock pay dividends?
UPB does not pay a dividend.
When does UPSTREAM BIO INC (UPB) report earnings?
UPSTREAM BIO INC (UPB) will report earnings on 2025-11-05.
What is the Price/Earnings (PE) ratio of UPSTREAM BIO INC (UPB)?
UPSTREAM BIO INC (UPB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-9.8).
What is the Short Interest ratio of UPSTREAM BIO INC (UPB) stock?
The outstanding short interest for UPSTREAM BIO INC (UPB) is 7.86% of its float. Check the ownership tab for more information on the UPB short interest.
UPB Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to UPB.
UPB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to UPB. While UPB has a great health rating, there are worries on its profitability.
UPB Financial Highlights
Over the last trailing twelve months UPB reported a non-GAAP Earnings per Share(EPS) of -9.8. The EPS decreased by -99.7% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.17% | ||
| ROE | -26.93% | ||
| Debt/Equity | 0 |
UPB Forecast & Estimates
8 analysts have analysed UPB and the average price target is 76.5 USD. This implies a price increase of 283.07% is expected in the next year compared to the current price of 19.97.
For the next year, analysts expect an EPS growth of 65.26% and a revenue growth 21.55% for UPB